Can taking metformin early for COVID-19 lower the odds of long COVID?
Yes. In this large NIH-funded trial, a 6-week course of metformin started soon after COVID-19 symptoms began cut the rate of long COVID roughly in half at six months. Doctors diagnosed long COVID in 0.56% of people who took metformin, compared to 1.17% of those who took a placebo.
Metformin is an old, cheap, and widely used diabetes pill. Researchers wanted to know if it could do something new: prevent the lingering illness many people develop after COVID-19. This study, called ACTIV-6, tested that idea in a careful, controlled way. The early results are encouraging, though a few details deserve a closer look.
What the data show
The trial enrolled 2,983 adults with mild-to-moderate COVID-19 who were treated as outpatients, meaning they were not in the hospital. Half took metformin and half took a placebo, a dummy pill with no active ingredient. People started the medicine within 7 days of their first symptoms and continued for 6 weeks.
By the six-month mark, the difference in clinician-diagnosed long COVID was striking. The risk ratio was about 0.50, which means metformin roughly halved the chance of a long COVID diagnosis. The researchers calculated a 96% posterior probability of efficacy, a statistical way of saying they were highly confident the drug truly helped. Importantly, no safety concerns came up during the study.
There is a caveat worth understanding. When researchers looked at a broader measure, any lingering symptoms at all, the benefit was smaller and did not cross the trial’s formal line for statistical significance. So the strongest signal was for a doctor’s formal diagnosis of long COVID, not for every minor symptom that lingers.
Dr. Kumar’s Take
What I find exciting here is the practicality. Metformin has been around for decades, costs very little, and we already understand its safety profile well. The idea that a familiar, inexpensive pill might cut the odds of long COVID in half is the kind of finding that could help a lot of people if it holds up.
I also appreciate that more than 83% of the people in this trial already had immunity, either from vaccination or a prior infection. That mirrors the real world today, so the results feel relevant to the patients I actually see. Still, I want to be honest about limits. The clearest benefit was for a formal long COVID diagnosis, while the effect on general lingering symptoms was softer. This is one strong trial, not the final word, and I would like to see the findings repeated before metformin becomes a routine recommendation.
Study Snapshot
ACTIV-6 was designed to be rigorous. It was quadruple-blinded, which means the participants, the doctors, the people handing out the pills, and the researchers analyzing the data all did not know who got metformin and who got placebo. That design helps prevent wishful thinking from coloring the results.
The trial ran across 90 sites in the United States and focused on outpatients with mild-to-moderate illness. By treating people early, within a week of symptoms, the researchers tested metformin during the window when the virus is most active. This setup makes the outcome easier to trust than a smaller or less controlled study would.
Who might benefit most
This trial points to people in the first days of a COVID-19 infection, before symptoms become severe. Because treatment started within 7 days of symptoms, the benefit appears tied to acting early rather than waiting. The results may matter most for adults who want to lower their long-term risk after catching the virus.
It is also reassuring that the benefit showed up in a population that already had widespread immunity. Many earlier long COVID studies were done before most people were vaccinated or previously infected, so their findings did not always apply now. Here, the modern mix of participants makes the takeaway more useful for today.
Practical Takeaways
- If you catch COVID-19, talk to your doctor early about your options, since this trial suggests the timing of treatment within the first 7 days may matter for preventing long COVID.
- Do not start metformin on your own, as it is a prescription medicine and this single trial is not yet enough to make it a standard recommendation for everyone.
- Keep your vaccinations up to date, because most people in this study already had immunity, which remains a proven layer of protection.
- Watch for lingering symptoms after an infection and bring them to your doctor, since early attention to long COVID can guide better care.
Related Studies and Research
- Normobaric oxygen treatment for mild-to-moderate depression: RCT
- Long-term oxygen treatment trial (LOTT) and health benefits
- Optimizing cardiopulmonary rehabilitation duration for long COVID
- Oxygen therapy during ADL rehabilitation in severe COVID-19
FAQs
How does metformin work to lower long COVID risk?
This trial measured outcomes, not the exact biological reason, so the precise mechanism is not proven here. Researchers have suggested that metformin may calm inflammation and may interfere with how the virus uses the body’s cells to multiply. By treating people early, within 7 days of symptoms, the drug acts when the virus is most active. More lab and clinical work is needed to confirm how the protection actually happens.
Is metformin safe to take for COVID-19?
In this trial, no safety concerns emerged among the nearly 3,000 adults studied, which is reassuring. Metformin has also been used safely for diabetes for many decades, so its side effect profile is well understood. The most common issues people report with metformin are mild stomach upset, such as nausea or loose stools. Even so, it is a prescription drug, so any use should be guided by your doctor.
Does this mean everyone with COVID-19 should take metformin?
Not yet. While the results are promising, this is a single trial, and the clearest benefit was for a formal long COVID diagnosis rather than for every lingering symptom. Medical guidelines usually change only after findings are repeated in more studies. For now, the smart move is to discuss your personal risk and options with your doctor rather than seeking the drug on your own.
Bottom Line
In a large, carefully run NIH trial, starting metformin within a week of COVID-19 symptoms cut the rate of clinician-diagnosed long COVID roughly in half at six months, with high statistical confidence and no safety concerns. The benefit was strongest for a formal diagnosis and weaker for general lingering symptoms, so this is a hopeful signal rather than a final verdict. Because most participants already had immunity, the results feel relevant to today’s population, and they make a strong case for more research into this cheap, familiar pill.
